KMT2A and leukemia: Our results revealed that the CACCC-box can further serve as a complementary reverse binding site for PATZ1, known for its regulatory effect in the cell cycle, WT1, whose mutations have been associated with congenital heart defects and KMT2A, which primarily has been related with leukemia, but has been found to also associate with congenital heart defects and cardiovascular diseases by regulating gene expression essential for cardiac development and function [6,55].